What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna Comeback

21 Feb 2026 · 5 min · 4 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: WSJ What’s News Episode - What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna Comeback

Episode Overview Date: February 21 Host: Jack Pitcher Description: This episode discusses the recent significant stock movements in the market, with a focus on Walmart's decline despite strong earnings, Omnicom's stock surge following cost-cutting measures, and Moderna's recovery after an FDA reversal.

Key Highlights

Market Movements

  • General Market Overview
  • The stock market experienced a muted week due to the holiday, but corporate earnings reports created underlying activity.
  • Positive sentiment returned for tech and growth stocks after a period of decline influenced by fears surrounding AI advancements.
  • The S&P 500 rose by 1.1%, the Dow increased by 0.3%, while the Nasdaq saw a gain of 1.5%.

Major Company Updates

  1. Walmart
  2. Earnings Report: Despite posting strong earnings that exceeded analysts’ expectations, Walmart saw its stock drop by 8%.
  3. Status Change: Walmart has been overtaken by Amazon as the largest company by annual revenue after 17 years.
  4. Investor Sentiment: Stock performance reflects concerns over valuation as the company provided conservative guidance amidst economic instability.
  1. Omnicom
  2. Stock Surge: Omnicom’s shares rose by 15% on the day of the earnings report and 21% for the week.
  3. Cost-Cutting Measures: The company announced it would double its cost-cutting target, planning to save $900 million primarily through workforce reductions.
  1. Moderna
  2. FDA Reversal: After initial negative sentiment regarding a seasonal flu shot, the FDA's decision to review Moderna's application after additional testing led to an 18% increase in its stock for the week.
  3. Market Reaction: Moderna's shares rallied by 6% on the announcement day and demonstrated recovery following a challenging period post-COVID-19 vaccine sales.

Impactful News

  • Supreme Court Ruling: The Supreme Court's decision to strike down President Trump's global tariffs provided a boost to stocks, although the ruling was largely anticipated.
  • Sector Performance:
  • Communication services and information technology were the best-performing sectors, while consumer staple companies fell sharply, indicating a shift away from defensive investments.

Conclusion Jack Pitcher's analysis provides an insightful overview of how major earnings reports and regulatory decisions are shaping market dynamics, illustrating the juxtaposition of traditional retail decline alongside technology and marketing sector resilience.

Further Reading More in-depth analysis and live market coverage are available on [WSJ.com](https://www.wsj.com).

---

Produced by: Alexis Moore Deputy Editor: Chris Zinsley Host: Jack Pitcher

*Enjoy the weekend! For more updates, visit wsj.com/future.*

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Market Overview: Corporate Earnings and Stock Movements

0:45 to 2:06

Analysis of the stock market's performance during the holiday week, focusing on tech and growth stocks.

“Stocks were relatively muted for the shorter holiday week, but there was no shortage of action under the surface, thanks to a big slate of corporate earnings.”

Walmart's Earnings and Market Position

2:06 to 2:58

Discussion about Walmart's quarterly earnings report and its impact on stock performance.

“Walmart lost a notable crown when it reported earnings on Thursday.”

Omnicom's Earnings and Cost-Cutting Strategy

2:58 to 3:39

Overview of Omnicom's financial performance and the decision to cut costs post-acquisition.

“Omnicom is the biggest marketing services and advertising conglomerate in the U.S., and it told investors it was doubling its cost-cut target following its acquisition of competitor IPG.”

Moderna's Stock Recovery Following FDA Reversal

3:39 to 4:21

Examination of Moderna's fluctuating stock prices and recent FDA decisions affecting the company.

“And the vaccine skepticism of Health and Human Services Secretary Robert F.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Jack Pitcher:That's pure automotive joy. I'm Peter, the owner of Muscle Car Junior. It started as a hobby, then I started posting about it. Before I knew it, I built a business restoring muscle cars on Facebook Marketplace and the community of car lovers on Instagram. Today, new customers send me WhatsApp messages from all over. Not bad for a hobby. Learn how Meta helps over 35 million American businesses like Peter's grow at meta.com slash community. Hey listeners, it's Saturday, February 21st. I'm Jack Pitcher for The Wall Street Journal, and this is What's News in Markets, our look at the biggest stock moves of the week and the news that drove them.

0:44Let's get to it. Stocks were relatively muted for the shorter holiday week, but there was no shortage of action under the surface, thanks to a big slate of corporate earnings. Investors seem to be regaining some confidence in tech and growth stocks, both of which have sold off for much of the year, over fears that rapid advancements in AI are going to render some software companies obsolete. But this week, communication services and information technology were the S &P 500's best performing sectors. Meanwhile, consumer staples companies, which are often seen as a safe haven, drop sharply. That signals a rotation away from the fear trade and back into other parts of the market.

1:27Then, of course, yesterday, the Supreme Court struck down President Trump's sweeping global tariffs. Last April, when they were first announced, the tariffs roiled markets. But a series of deals and carve-outs in the months since helped calm investors' fears. Stocks turned higher after the Supreme Court's decision, but analysts noted the ruling had been largely expected. And Trump said he'd keep the tariffs in place under a different authority. For the week, the S &P 500 rose 1.1%, while the Dow was 0.3 % higher. The tech-heavy Nasdaq added 1.5%.

2:06Walmart lost a notable crown when it reported earnings on Thursday. After 17 years of being the largest company in the U.S. by annual revenue, the retailer has officially been passed by Amazon. Still, Walmart's quarterly results were actually pretty strong, beating analysts' estimates for sales. Investors were not impressed. In the last three years, Walmart's shares have risen around 500 % thanks to remarkable results. And that's made the stock expensive by traditional valuation metrics, which leaves it susceptible to disappointment if forecasts are anything less than stellar. Walmart CFO John David Rainey told investors on Thursday that the company is giving conservative guidance because the economic backdrop is somewhat unstable.

2:52Walmart shares were among the S &P's worst performers this week, dropping 8%. Investors found more to like with Omnicom's earnings, but employees there may be feeling jittery. Omnicom is the biggest marketing services and advertising conglomerate in the U.S., and it told investors it was doubling its cost-cut target following its acquisition of competitor IPG. It expects to cut$900 million in costs this year, primarily by reducing headcount. Investors cheered the news, sending Omnicom shares up 15 % on Thursday and 21 % for the week, making them the S &P's best performer.

3:38The vaccine maker Moderna has been reeling in the years since sales of its COVID-19 vaccine peaked. And the vaccine skepticism of Health and Human Services Secretary Robert F. Kennedy Jr. has been hitting its shares more recently. But a major reversal from the Food and Drug Administration on Wednesday helped turn sentiment around. Last week, the FDA said it would not review Moderna's application for a new seasonal flu shot. The decision shocked investors. But the regulator has since had a change of heart, saying it'll begin review of the new shot after Moderna agreed to additional testing in the elderly.

4:13Moderna shares rallied 6 % on Wednesday and 18 % on the week, putting them among the best performers in the S &P. And now you know what's news in markets this week. You can read about more stocks that moved on the week's news in our live markets coverage on WSJ.com. Today's show was produced by Alexis Moore with Deputy Editor Chris Zinsley. I'm Jack Pitcher. Have a great weekend.

5:04Discounted rates by visiting wsj.com slash future. That's wsj.com slash future.

From the publisher

Why did Walmart fall on strong earnings? And how are Omnicom’s big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna’s fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

More from WSJ What’s News

All 335 episodes
What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna ComebackWSJ What’s News · 5 min
Listen in VO